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Abstract
Objective: To study the distribution of I/D polymorphic marker of the ACE gene in Uzbek patients with unstable angina, 
depending on the presence of family history of CHD compared with healthy individuals. Materials and methods: There were 
examined 125 Uzbek patients with unstable angina (class IIB by E. Braunwald et al., 1989). In patients with unstable angina 63 
patients (the 1st group) had and 62 patients (the 2nd group) had no a family history of CHD. Control group included 45 healthy Uzbek 
subjects without CHD and family history of CHD. The genomic DNA was isolated from the peripheral blood lymphocytes following 
standard protocol using the DiatomTM DNA Prep 200 kit (produced by LLC “Laboratory IsoGene”). I/D polymorphism of the ACE 
gene was detected according to Cambian F. et al. (1992). Results: In a comparative analysis of both groups, patients showed similarity 
in the baseline clinical, hemodynamic and biochemical parameters; however, the 1st group had significant higher IMC thickness of 
the carotid arteries and hsCRP levels. Simultaneously, patients with a family history of CHD, compared with the healthy group of 
individuals, were noted to have a significantly higher prevalence of the D/D genotype [OR: 3.46 (95% CI: 1.18-8.11; P=0.035)] and 
“damaging” D-allele [OR: 2.47 (95% CI: 1.40-4.34; P=0.002)]. Conclusion: The presence of a family history of the coronary heart 
disease among Uzbek patients with unstable angina was associated with the higher frequency of the “damaging” D-allele of the ACE 
I/D gene polymorphism, accompanied by an increase in the thickness of the intima-media complex of the carotid arteries and level 
of high-sensitivity C-reactive protein. 
Key words: I/D polymorphism of the ACE gene, unstable angina, a family history of CHD, intima-media complex, C-reactive 
protein.
Introduction
In the development of coronary heart disease 
(CHD), it is well known that besides phenotypic environmental 
factors  [1,2],  there  is  also  a  genetic  predisposition  to  the 
disease playing an important role. Conducting a simultaneous 
analysis of all the candidate genes is currently the complex 
problem to contend with; therefore, it is important to identify 
the group of genes with potentially the largest contribution to 
the pathogenesis of the disease. Angiotensin-converting enzyme 
(ACE), the main enzyme of the renin-angiotensin system (RAS) 
plays an important role in hemodynamics and blood pressure 
regulation,  the  control  of  the  water-salt  metabolism  and  cell 
growth. Currently, there is sufficient experimental and clinical 
laboratory data indicating a direct correlation between ACE 
activity and the severity of atherosclerosis [3].
Objective
To study the distribution of the I/D polymorphic marker 
of the ACE gene in Uzbek patients with unstable angina with a 
family history of CHD compared with healthy individuals.
Material and Methods
The study included patients receiving inpatient treatment 
in the Republican Specialized Center of Cardiology (Tashkent, 
Uzbekistan). In this study, we examined 125 Uzbek patients 
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with unstable angina (class IIB by E. Braunwald et al., 1989) 
and  hypercholesterolemia  (low-density  lipoprotein  (LDL) 
cholesterol > 100 mg/dL). The control group included 45 healthy 
Uzbek subjects without clinical and indicative diagnostic 
signs of CHD (based on exercise testing) and with no family 
history of CHD. Both groups were matched by age and sex. 
However, patients with myocardial infarction (MI), transferred 
within the last three months, insulin-dependent patients with 
diabetes type 2, those patients with II-III degree hypertension 
(BP>159/99 mmHg), hypotension (BP<100/60 mmHg), and 
patients with severe disorders of cardiac rhythm and conduction 
((sick sinus syndrome, II-III degree atrioventricular (AV) block, 
sinoatrial (SA) block, frequent ventricular premature beats, 
atrial fibrillation), chronic obstructive pulmonary disease, with 
chronic heart failure higher than I FC (NYHA), chronic renal 
and hepatic failure were excluded from the study. Also, patients 
treated long term with lipid-lowering drugs and ACE prior to the 
study were excluded. For an objective assessment of the level of 
the inflammatory biomarkers, patients with acute or exacerbated 
chronic  infectious,  inflammatory  and  autoimmune  diseases 
within one month after the onset of a full clinical and laboratory 
remission were not included. For an objective assessment 
of the level of the inflammatory biomarkers, other exclusion 
criteria included, the presence of acute infectious disease or 
exacerbation of chronic infectious disease, inflammatory and 
autoimmune diseases in less than one month after complete 
clinical and laboratory remission. All patients signed informed 
consent prior to participation in the study.
Family history: Evaluation of family history was done 
based on the survey using the standard questionnaire drawn up 
by WHO, “Family History”. We registered the occurrence of 
death (as a result of myocardial infarction or stroke) in 1st degree 
relatives (parents, siblings, and children), prior myocardial 
infarction, and the presence of hypertension. Family history was 
considered “burdened” for a patient with two or more affected 
relatives. Initially, the diagnosis of unstable angina was verified 
based on any of the following criteria: patients with complaints 
characteristic of pain dynamics against the background of the 
therapy; patient history including the presence of angina or 
myocardial infarction (not more than three months) and patients 
with  the  dynamics  of  ECG  results  (transient  ST-depression 
more than 1 mm, the lack of ST elevations), lack of increase   
in troponin I levels, ECG Holter monitoring and patients, 
on echocardiography, revealing signs of local contractility 
disturbances (hypokinesia, dyskinesia), and evaluation of global 
left ventricular contractility.
Ultrasound examination of carotid arteries: The thickness 
of  the  intima-media  complex  (IMC)  of  the  common  carotid 
artery was determined by scanning the B-mode color Doppler 
flow mapping on the ultrasound system «ALOKA - Multi View» 
(Japan) linear transducer with a frequency of 7 MHz (20m).
Echocardiography: ECGs was performed on the 
echocardiograph «ALOKA - Multi-View» using the standard 
method recommended by the American Association of 
Echocardiography. Measurements included end-diastolic size, 
end-systolic  left  ventricular  (LV)  size,  LV  ejection  fraction, 
left  ventricular  posterior  wall  thickness  (LVPWT)  and 
interventricular septum (IVST) in diastole. All measurements 
were performed for at least five cardiac cycles, and then the 
average results were taken.
ECG Holter monitoring: ECG Holter monitoring s was 
performed to verify the diagnosis in patients with unstable 
angina, according to the standard method on the unit CardioLab, 
(HAI, Ukraine).
Determination  of  the  lipid  profile:  The  lipid  profile 
includes total cholesterol, triglycerides, HDL cholesterol, LDL 
and VLDL cholesterol (very low density), and the coefficient of 
atherogenicity. Blood sampling was performed on the morning 
following hospital admission, 12 hours post fasting, with blood 
drawn from the cubital vein, keeping the patient in the horizontal 
position. Determination of the blood lipid levels was performed 
to check total cholesterol (TC), high density lipoprotein 
(HDL), and triglycerides (TG), using the enzymatic method 
on  the  biochemical  analyzer  «Daytona»  (RANDOX,  UK). 
The  concentration  of  LDL-C  was  determined  by  employing 
Friedwald formula:
LDL-C = TC - HDL - TG / 5 (mg / dl)
The atherogenic ratio (AR) was determined using the formula:
AR = (Cholesterol - HDL cholesterol) / HDL-C (RU)
TC in blood serum <200 mg/dL, HDL-C > 40 mg/dL, TG <150 
mg/dl, LDL-C <100 mg/dl were considered normal values. 
The  concentration  of  high  sensitive  C-reactive  protein 
was  determined  by  the  highly  sensitive  particle-enhanced 
turbidimetric  immunoassay  method  with  latex  amplification 
using  “Daytona»  (RANDOX,  UK).  The  levels  of  the 
apolipoproteins A-1, B were determined with the biochemical 
autoanalyzer “Daytona» (RANDOX, UK), by particle-enhanced 
turbidimetric immunoassay, using a monospecific antibody to 
human apo-B  to calculate the apo-B/apo-A ratio. The value of 
the coefficient was considered normal when the ratio was <1.0.
Determination of the concentration of Lp (a) (mg / dL) 
in the serum was performed with ELISA, using a monospecific 
antibody to human Lp (a). A lipoprotein (a) level higher than 30 
mg / dL was considered an increased value.
Genotyping: The genomic DNA was isolated from the 
peripheral blood lymphocytes following standard protocol 
using the DiatomTM DNA Prep 200 kit (produced by LLC 
“Laboratory IsoGene”). I/D polymorphisms of the ACE gene 
by the polymerase chain reaction (PCR) was performed in the 
laboratory of Functional Human Genomics, at the Institute 
of Genetics and Plant Experimental Biology, Academy of 
Sciences of RU using the PCR Systems 2700 Thermal Cycler 
(“Applied Biosystems”, USA) and in the laboratory of Arterial 
Hypertension and MHI RSCC on the GeneAmp PCR Systems 
9700  Thermal  Cycler  («Applied  Biosystems»,  USA).  The 
sequence of primers was followed using the study by Cambian 
F.  et al. [4]. 
ACE1 5´- CTG GAG ACC ACT CCC ATC CTT TC - 3´
ACE2 5´- GAT GTG GCC ATC ACA TTC GTC AGA T - 3´
Statistical data analysis was done using the software 
package Statistica 6.0, and Microsoft Excel spreadsheets. Results 
are presented as the arithmetic mean and standard deviation (M 
± SD); statistical significance of the measurements was done by 
comparing the average values   determined by Student’s test (t) 
with the computation of error probability (P) for checking the 
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Mann-Whitney for two samples) was done when the distribution 
of the variables studied varied from normal. 
The genotype distributions in control subjects conformed 
to  Hardy-Weinberg  equilibrium.  To  compare  the  genotype 
frequencies, we used the standard test χ2 Pearson. To reject 
the null hypothesis (no difference) the levels of statistical 
significance p <0.05 were taken. The relative risk (odd ratio, 
OR) of the disease at a particular genotype was calculated by 
the multiplicative model of inheritance. OR was specified with a 
95% confidence interval.
Result
In patients with unstable angina 63 (50.4%) patients (the 
1st group) had and 62 (49.6%) patients (the 2nd group) had no a 
family history of CHD (Table 1). In a comparative analysis of 
both groups, patients showed similarity in the baseline clinical, 
hemodynamic and biochemical parameters (Tables 2 & 3); 
however, the patients of the 1st group had higher IMC thickness 
of the carotid arteries and hsCRP levels. 
Based  on  the  results  of  genotyping  no  significant 
differences were observed in the genotype distribution and 
carrying of the “damaging” D allele of the ACE I/D gene 
polymorphism between patients with unstable angina (n = 125) 
and the healthy individuals (Table 4). Simultaneously, patients 
with a family history of CHD, compared with the healthy 
group of individuals, were noted to have a significantly higher 
prevalence  of  the  D/D  genotype  and  “damaging”  D-allele. 
Besides, they also showed less frequent occurrence of the I/I 
genotype and less frequently occurring I allele.
Table 1
Clinical and demographic characteristics of the subjects examined  
Parameters
Patients with 
UA (n=125)
Healthy 
subjects (n=45)
Age 54.8±9.5 53.6±11.3
Sex (male/female), n (%) 71/54 (57/43) 26/19 (58/42)
“Burdened” FH of CHD, n (%) 63 (50.4) 0
Diabetes mellitus, n (%) 26 (20.8) 0
Heart rate, beats per min. 78.2±12.6*** 68.6±5.9
SBP, mmHg 136.0±21.4*** 120.7±8.1
DBP, mmHg 86.5±11.7*** 77.2±5.2
Note: *** - Р<0.001, significance of differences between groups;
          FH- family history. 
Table 2
 The initial clinical, hemodynamic, and biochemical parameters in 
patients with unstable angina, depending on the presence of family 
history of CHD
Parameters
1st group
(n=63)
2nd group
(n=62)
Age 53.1±10.3 56.4±8.4
Sex (male/female), (%) 57.1/42.9 56.5/43.5
Duration of CHD, years 5.6±4.2 5.5±4.5
Arterial Hypertension I stage, (%) 95.2 88.7
History of myocardial infarction,  (%) 33.3 38.7
Diabetes mellitus,  (%) 22.2 19.4
History of stroke,  (%) 7.9 3.2
Frequency of angina attacks in a week 29.1±9.1 28.2±7.5
Intake of nitroglycerin in a week 20.3±8.0 20.1±5.2
Heart rate, beats / min 78.1±12.8 78.2±12.4
Systolic BP, mmHg 136.3±19.5 135.9±23.4
Diastolic BP, mmHg 86.4±11.3 86.6±12.2
LV EDV, mL 140.5±30.9 149.4±30.5
LV ESV, mL 53.2±23.8 58.5±21.8
LVEF, % 62.7±9.2 61.8±8.3
IMC, right 1.02±0.22 0.96±0.20
IMC, left 1.02±0.23* 0.93±0.22
Note: * - Р<0.001, significance of differences between groups.
          
Table 3 
The baseline parameters of lipid metabolism, biomarkers of lipid 
metabolism  and  inflammation  in  patients  with  unstable  angina, 
depending on the presence of family history of CHD
Parameters
1st group 
(n=63)
2nd group
 (n=62)
Total cholesterol, mg/dL 218.8±49.3 213.9±39.2
TG, mg/dL 193.7±72.9 188.7±88.5
LDL cholesterol, mg/dL 139.0±42.7 136.8±37.3
HDL cholesterol, mg/dL 38.0±9.0 38.8±8.6
VLDL cholesterol, mg/dL 40.5±17.4 41.4±22.0
Atherogenic ratio (RU) 4.9±1.7 4.7±1.3
Apo A, mg/dL 131.1±41.0 126.2±26.1
Apo B, mg/dL 102.0±28.4 99.5±27.8
Apo A/Apo B, unit 0.8±0.3 0.8±0.3
Lipoprotein (a) mg/dL 34.4±16.3 39.1±18.2
hsCRP, g/L 12.0±10.8* 8.2±8.4
Note: * - Р<0.05, significance of differences between groups.
Table 4
 Distribution of the I/D polymorphic marker of the ACE gene in Uzbek 
patients with unstable angina, based on family history
Genotypes, 
alleles
Patients 
with UA
 (n = 125)
1st group
(n=63)
2nd group
(n=62)
Healthy 
subjects 
(n=45)
D/D-
genotype
29 (23%)
OR: 2.42
CI: 0.87-6.69
ns
19 (30%)
OR: 3.46
CI: 1.18-8.11
Р=0.035
10 (16%)
OR: 1.54
CI: 0.49-4.86
ns
5(11%)
I/D-
genotype
54 (43%)
OR: 1.04
CI: 0.52-2.07
ns
30 (48%)
OR: 1.24
CI: 0.58-2.69
ns
24 (39%)
OR: 0.86
CI: 0.40-1.89
ns
19(42%)
I/I-
genotype
42 (34%)
OR: 0.58
CI: 0.29-1.16
ns
14 (22%)
OR: 0.33
CI: 0.14-0.75
(P=0.014)
28 (45%)
OR: 0.94
CI: 0.44-2.03
ns
21(47%)
D-allele 112 (45%)
OR: 1.71
CI: 1.03-2.84
Р=0.051
68 (54%)
OR: 2.47
CI: 1.40-4.34
Р=0.002
44 (36%)
OR: 1.16
CI: 0.65-2.06
ns
29(32%)
I-allele 138 (55%)
OR: 0.59
CI: 0.35-0.97
(Р=0.051)
58 (46%)
OR: 0.41
CI: 0.23-0.71
(Р=0.002)
80 (65%)
OR: 0.86
CI: 0.49-1.54
ns
61(68%)
Note:  P – Significance of differences relative to the group of healthy individuals
 (in parentheses are P values relative to the group of healthy patients with a 
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A comparison of the characteristics of I/D polymorphism 
of the ACE gene between the 1st  group (n = 63) and the 2nd group 
(n = 62) of patients revealed that patients with a family history 
showed a significantly higher frequency of the D allele (54% vs. 
36%) [OR: 2.13 (95% CI: 1.29-3.54; p = 0.005)]. 
At the same time, I/I genotype was found more frequently 
(45% vs. 22%) in patients with no family history of CHD [OR: 
4.25 (95% CI: 1.96-9.2; P<0.001)], whereas when considering 
the  frequency  of  the  D/D  and  I/D-genotype  distribution,  the 
differences were not significant.
Discussion
The uniqueness of this study lies in the comparison of 
the distribution of alleles of these specific genes in the patients 
studied, based on the family history of CHD. This allowed for 
a comparison of the prevalence of genetic markers in people 
who may have been predominantly under the influence of the 
“phenotype” of environmental factors with the “tuning fork” of 
the patient group with the crucial contribution of genetic factors. 
It is well known that angiotensinogen and ACE are 
the main elements of RAS and greatly contribute to the 
development of cardiovascular disease. The role of the I/D 
polymorphism of the ACE gene in the development of acute 
myocardial ischemia, which is realized through the appropriate 
enzyme, is multifaceted. Experimental studies have shown the 
connection between the ACE gene D/D genotype and excessive 
vasoconstriction, a tendency for thrombosis, and a disturbance 
in endothelial function [5,6]. In this regard, several studies have 
been conducted to analyze the relationship between the I/D 
polymorphism of the ACE gene and the development of CVD. 
An analysis of 145 independent studies (a sample including 
49,959 people) revealed that the presence of the ACE gene 
D/D variant is associated with an increased risk of developing 
atherosclerotic and vascular disease [7]. The presence of the D 
allele homozygotes corresponds to an increased risk of coronary 
heart disease by an average in 1.3 times according to 30 studies. 
According to N.A. Malygina et al., the ACE gene D/D genotype 
and D allele may serve as the criteria for identifying patient 
groups which are at high risk for myocardial infarction and 
coronary heart disease [8]. In the REGRESS study, according 
to a two-year monitoring of 782 men with stable angina treated 
with pravastatin, the incidence of myocardial infarction was 
significantly  higher  among  those  patients  possessing  the 
D/D genotype of the ACE gene than in patients having both 
the D/D genotype of the ACE gene and the C/C genotype of 
the angiotensin II receptor gene [9]. The results of this study 
showed that among patients with unstable angina, a marked 
accumulation of the deleterious D alleles of RAS was expressed 
more in patients with a family history of CHD. Simultaneously, 
in patients with a family history, higher values   of carotid IMC 
and hsCRP were noted, which indicate an unfavorable outcome 
[10,11]. A possible relationship of these factors along with the 
accumulation of «D» allele of the I/D polymorphic marker of the 
ACE gene warrants further study.
Conclusion
The presence of a family history of coronary heart disease 
among Uzbek patients with unstable angina was associated with 
the higher frequency of the “damaging” D-allele of the ACE 
I/D gene polymorphism, accompanied by an increase in the 
thickness of the intima-media complex of the carotid arteries 
and level of high-sensitivity C-reactive protein. 
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